

03C0

#5

Patent
Page 1 of 3

MAIL DATE CANCELLED
OIP
FEB 27 2002
PATENT & TRADEMARK OFFICE 848

OIP E
FEB 28 2002
PATENT & TRADEMARK OFFICE 848

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Application: Claes Ohlsson et al.
Serial No. : 09/994,292
Filed : November 26, 2001
For : ESTROGEN RECEPTORS
Examiner :
Attorney Docket : 102296-100
Group Art Unit :
Confirmation No. : 8841

I hereby certify that this correspondence is being deposited with
the United States Postal Service as first class mail in an
envelope addressed to: Assistant Commissioner for Patents,
Washington, D.C. 20231 on 7 FEB 2002.

By Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant(s)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully
requested to consider the references cited on attached Form PTO-
1449. A copy of each reference (if not previously submitted) is
enclosed. It is respectfully requested that the information be
expressly considered during the prosecution of this application,
and that the reference(s) be made of record therein and appear
among the "References Cited" on any patent to issue therefrom.

[X] 1. This Information Disclosure Statement is being filed
within three months of the U.S. filing date OR before the
mailing date of a first Office Action on the merits. No
certification or fee is required.

[] 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

[] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1); and no fee is required under 37 C.F.R. §1.17(p).

[] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).

[] Please charge Deposit Account No. 23-1665 in the amount of \$180.00 in payment of the fee under 37 C.F.R. §1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.

[] A check in the amount of \$180.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(p).

[] 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.

[] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).

- [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e) (2).
- [] Please charge Deposit Account No. 23-1665 in the amount of \$130.00 in payment of the fee under 37 C.F.R. §1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.
- [] A check in the amount of \$130.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(i)(1).

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Respectfully submitted,

CLAES OHLSSON ET AL.

By



Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

WIGGIN & DANA
One Century Tower
New Haven, CT 06508-1832

Telephone : (203) 498-4400
Telecopier: (203) 782-2889

Date: 7 FEB 2002



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application : Claes Ohlsson et al.
Serial No. : 09/994,292
Filed : November 26, 2001
For : ESTROGEN RECEPTORS
Examiner :
Attorney Docket : 102296-100
Group Art Unit :
Confirmation No. : 8841

* * * * *

I hereby certify that this correspondence is being deposited
with the United States Postal Service as first class mail in an
envelope addressed to: Assistant Commissioner for Patents,
Washington, D.C. 20231 on 7 FEB 2002.

By Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant(s)

* * * * *

INFORMATION DISCLOSURE LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The undersigned represents that the closest art of which he
is presently aware has been cited herein and understands that
this statement shall not be construed as a representation that
no better art exists or that a thorough patentability search has
been made.

The undersigned further represents that the filing of this
Information Disclosure Statement shall not be construed to be an
admission that the information cited in the Statement is, or is
considered to be, material to patentability as defined in 37
C.F.R. § 1.56(b).

1. PCT WO 00/76529 A2 filed June 12, 2000.
2. PCT WO 00/70079 A1 filed May 10, 2000.
3. PCT WO 00/66767 filed April 28, 2000.
4. PCT WO 00/19994 A1 filed October 1, 1999.
5. U.S. Patent No. 5,183,736 issued February 2, 1993 to Pfahl et al.
6. CAS Abstract No. 2000:832646, Ohlsson et al., Biochem. Biophys. Res. Commun. (2000), 278(3), pp. 640-645.
7. CAS Abstract No. 2000:818447, Heine et al., Proc. Natl. Acad. Sci. USA (2000), 97(23), pp. 12729-12734.
8. CAS Abstract No. 1998:206686, Ke et al., Endocrinology (1998), 139(4), pp. 2068-2076.
9. PCT WO 00/39120 filed December 30, 1999.
10. PCT WO 00/31112 filed November 18, 1999.

If the Examiner has any questions or feels that a discussion with Applicants' representative would expedite prosecution, the Examiner is invited and encouraged to contact Applicants' undersigned representative at the telephone number listed below.

Respectfully submitted,

CLAES OHLSSON ET AL.

By Todd E. Garabedian

Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant(s)

WIGGIN & DANA
One Century Tower
New Haven, CT 06508

Date: 7 FEB 2002

Telephone: (203) 498-4400
Fax: (203) 782-2889